Patent: 7,897,635
✉ Email this page to a colleague
Summary for Patent: 7,897,635
Title: | HIV protease inhibitors |
Abstract: | Compounds useful for inhibiting HIV protease are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating wild-type HIV and of multidrug-resistant strains of HIV, also are disclosed. |
Inventor(s): | Ghosh; Arun K. (River Forest, IL), Bilcer; Geoffrey M. (Chicago, IL), Devasamudram; Thippeswamy (Chicago, IL) |
Assignee: | The Board of Trustees of the University of Illinois (Urbana, IL) |
Application Number: | 11/593,665 |
Patent Claims: | see list of patent claims |
Details for Patent 7,897,635
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2022-03-12 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2022-03-12 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2022-03-12 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2022-03-12 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2022-03-12 |
Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2022-03-12 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | ⤷ Try a Trial | 2022-03-12 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |